Acquisition by Weinand Dieter of 5000 shares of Coya Therapeutics, at 5.73 subject to Rule 16b-3
COYA Stock | 6.11 0.40 7.01% |
About 55% of Coya Therapeutics,'s investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Coya Therapeutics, Common suggests that some traders are interested. The current market sentiment, together with Coya Therapeutics,'s historical and current headlines, can help investors time the market. In addition, many technical investors use Coya Therapeutics, Common stock news signals to limit their universe of possible portfolio assets.
Coya |
Filed transaction by Coya Therapeutics, Common Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Coya Therapeutics, Fundamental Analysis
We analyze Coya Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coya Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coya Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Coya Therapeutics, is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Coya Therapeutics, Common Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Coya Therapeutics, stock to make a market-neutral strategy. Peer analysis of Coya Therapeutics, could also be used in its relative valuation, which is a method of valuing Coya Therapeutics, by comparing valuation metrics with similar companies.
Peers
Coya Therapeutics, Related Equities
CUE | Cue Biopharma | 27.52 | ||||
LTRN | Lantern Pharma | 13.33 | ||||
INZY | Inozyme Pharma | 7.72 | ||||
CGTX | Cognition Therapeutics | 5.56 | ||||
GANX | Gain Therapeutics | 4.74 | ||||
INAB | In8bio | 3.57 | ||||
DRMA | Dermata Therapeutics | 2.88 | ||||
ABOS | Acumen Pharmaceuticals | 2.70 | ||||
OPT | Opthea | 1.90 | ||||
TERN | Terns Pharmaceuticals | 1.41 | ||||
STRO | Sutro Biopharma | 1.04 | ||||
HLVX | Hillevax | 0.48 | ||||
TCRX | Tscan Therapeutics | 0.65 | ||||
DAWN | Day One | 0.94 | ||||
NAMSW | NewAmsterdam Pharma | 1.95 | ||||
FENC | Fennec Pharmaceuticals | 2.23 | ||||
CNTA | Centessa Pharmaceuticals | 2.80 |
Complementary Tools for Coya Stock analysis
When running Coya Therapeutics,'s price analysis, check to measure Coya Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coya Therapeutics, is operating at the current time. Most of Coya Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Coya Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coya Therapeutics,'s price. Additionally, you may evaluate how the addition of Coya Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stocks Directory Find actively traded stocks across global markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |